How drugmakers can navigate the program’s pricing challenges and regulatory developments.
Kyle Forcier
Advertisement
Articles by Kyle Forcier
Contracts with payers that contain terms based on outcomes can highlight a drug's value
Advertisement
Latest Updated Articles
- The potential for outcomes-based contracting
Published: October 30th 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models
2
Cambrex Commits $120 Million to Grow US API Manufacturing
3
How Biopharma Companies Can Optimize Field Reimbursement Models
4
BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal
5
